Neurogene (NGNE) Earnings Date & Reports

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

NGNE is expected to report earnings to fall 25.00% to -2 cents per share on November 14

Q3'23

Est.

$-0.03

Q2'23

Est.

$-0.04

Q1'23

Missed

by $0.04

Q4'22

Missed

by $0.05

Q3'22

Beat

by $0.06

The last earnings report on August 16 showed earnings per share of -3 cents, meeting the estimate of -3 cents. With 190.04K shares outstanding, the current market capitalization sits at 163.87M.

View a ticker or compare two or three

Compare

NGNE